TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) With Persistent Asthma
Brief Summary: This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.


Options:
A: Arm Label: GW642444M 25mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M, Drug: placebo | Arm Label: GW642444M 50mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M | Arm Label: GW642444M 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M, Drug: placebo | Arm Label: GW642444H 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444H, Drug: placebo | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: GW642444M; Assigned to Arm(s): GW642444M 100mcg, GW642444M 25mcg, GW642444M 50mcg | Intervention Type: DRUG; Name: GW642444H; Assigned to Arm(s): GW642444H 100mcg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): GW642444H 100mcg, GW642444M 100mcg, GW642444M 25mcg, placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) With Persistent Asthma
Brief Summary: This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1
B: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone propionate
C: Arm Label: QMF149 150/80 μg; Type: EXPERIMENTAL; Interventions: Drug: QMF149 150/80 μg | Arm Label: MF 200 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: MF 200 μg | Intervention Type: DRUG; Name: QMF149 150/80 μg; Assigned to Arm(s): QMF149 150/80 μg | Intervention Type: DRUG; Name: MF 200 μg; Assigned to Arm(s): MF 200 µg
D: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients.
Brief Summary: To assess the efficacy of systemic corticosteroids alone as first-line treatment of Churg-Strauss syndrome without poor-prognosis factors as defined by the five-factor score (FFS=0), and to compare the efficacy and safety of azathioprine vs pulse cyclophosphamide as adjunctive immunosuppressive therapy to treat failure or relapse


Options:
A: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Azathioprine: 2 mg/kg/day; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Intravenous immunoglobulins (human immunoglobulins G); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease
Brief Summary: This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior adjuvant therapy (yes or no), measurable or non-measurable disease, and center.


Options:
A: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 and cisplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: TS-1 | Intervention Type: DRUG; Name: TS-1 and cisplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2
C: Arm Label: IP Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: IP Paclitaxel | Intervention Type: DRUG; Name: IP Paclitaxel; Assigned to Arm(s): IP Paclitaxel
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1/Cisplatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU/cisplatin | Intervention Type: DRUG; Name: S-1/Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-FU/cisplatin; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss
Brief Summary: With this clinical trial the investigators will analyze whether the rate of pregnancy losses before the 24th week of gestation can be reduced by dalteparin treatment in habitual aborters.


Options:
A: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
B: Arm Label: ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Klexane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane | Arm Label: Aspirin and Enoxaparine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Klexane and ASA | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): ASA | Intervention Type: DRUG; Name: Klexane; Assigned to Arm(s): Klexane | Intervention Type: DRUG; Name: Klexane and ASA; Assigned to Arm(s): Aspirin and Enoxaparine
C: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
D: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss
Brief Summary: With this clinical trial the investigators will analyze whether the rate of pregnancy losses before the 24th week of gestation can be reduced by dalteparin treatment in habitual aborters.


Options:
A: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
B: Arm Label: low molecular weight heparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin Sodium | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin Sodium; Assigned to Arm(s): low molecular weight heparin
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: dalteparin sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin sodium | Intervention Type: DRUG; Name: dalteparin sodium; Assigned to Arm(s): dalteparin sodium
D: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study
Brief Summary: Thyroidectomy is an operation that is commonly performed. After an operation a pressure dressing by Hypafix is usually used due to the belief that it will help to reduce complications such as post-operative bleeding or haematoma. However, the practice is uncomfortable to patients and makes it hard to detect early haematomas.

We carried out a prospective randomised study to study the role of pressure dressing after thyroid surgery by evaluating the amount of fluids collected in the operative bed by ultrasonography compared with normal dressing.


Options:
A: Arm Label: I-ZIP Ocular Bandage; Type: EXPERIMENTAL; Interventions: Device: I-ZIP Ocular Bandage | Arm Label: Oasis 24 hour Soft Shield Collagen Corneal Shield; Type: ACTIVE_COMPARATOR; Interventions: Device: Oasis 24 Hour Soft Shield Collagen Corneal Shield | Intervention Type: DEVICE; Name: I-ZIP Ocular Bandage; Assigned to Arm(s): I-ZIP Ocular Bandage | Intervention Type: DEVICE; Name: Oasis 24 Hour Soft Shield Collagen Corneal Shield; Assigned to Arm(s): Oasis 24 hour Soft Shield Collagen Corneal Shield
B: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pressure dressing | Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Procedure: Normal dressing | Intervention Type: PROCEDURE; Name: Normal dressing; Assigned to Arm(s): Experimental group | Intervention Type: PROCEDURE; Name: Pressure dressing; Assigned to Arm(s): Control group
C: Arm Label: Silver Eluting Dressing; Type: EXPERIMENTAL; Interventions: Other: Surgical dressing | Arm Label: Standard Guaze; Type: ACTIVE_COMPARATOR; Interventions: Other: Surgical dressing | Intervention Type: OTHER; Name: Surgical dressing; Assigned to Arm(s): Silver Eluting Dressing, Standard Guaze
D: Arm Label: Mepore Self-adhesive absorbent dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Mepore Self-adhesive absorbent dressing | Arm Label: AQUAGEL Ag Hydrofiber Wound Dressing; Type: EXPERIMENTAL; Interventions: Device: AQUAGEL Ag Hydrofiber Wound Dressing | Intervention Type: DEVICE; Name: AQUAGEL Ag Hydrofiber Wound Dressing; Assigned to Arm(s): AQUAGEL Ag Hydrofiber Wound Dressing | Intervention Type: DEVICE; Name: Mepore Self-adhesive absorbent dressing; Assigned to Arm(s): Mepore Self-adhesive absorbent dressing

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Client Centred 'Tune-ups': do They Enhance Community Reintegration and Mobility in Stroke Survivors?
Brief Summary: Once discharged from hospital many stroke survivors deteriorate medically, physically and in their mobility function and many report their level of function and quality of life to be poor 12 months after inpatient rehabilitation. There is an identified need for follow-up examinations of community dwelling stroke survivors to monitor changes in function and it has been suggested that maintenance therapy could curtail declines in function. The purpose of this trial is to determine whether brief periods of intense client-centered rehabilitation therapy (tune-ups) provided at 6 month intervals can alter the natural progression of impairment (physical capacity), function and community reintegration following stroke.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: functional rehabilitation nursing program | Arm Label: control group; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: OTHER; Name: functional rehabilitation nursing program; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control group
B: Intervention Type: BEHAVIORAL; Name: Conventional UK Physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased intensity of UK conventional physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: UK conventional physical therapy plus functional strength training; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: physical rehabilitation | Intervention Type: BEHAVIORAL; Name: physical rehabilitation; Assigned to Arm(s): Intervention
D: Arm Label: Dual tDCS + motor training; Type: EXPERIMENTAL; Interventions: Device: tDCS, Behavioral: Motor training | Arm Label: Anodal tDCS + motor training; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS, Behavioral: Motor training | Arm Label: Sham tDCS + motor training; Type: SHAM_COMPARATOR; Interventions: Device: tDCS, Behavioral: Motor training | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Anodal tDCS + motor training, Dual tDCS + motor training, Sham tDCS + motor training | Intervention Type: BEHAVIORAL; Name: Motor training; Assigned to Arm(s): Anodal tDCS + motor training, Dual tDCS + motor training, Sham tDCS + motor training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Client Centred 'Tune-ups': do They Enhance Community Reintegration and Mobility in Stroke Survivors?
Brief Summary: Once discharged from hospital many stroke survivors deteriorate medically, physically and in their mobility function and many report their level of function and quality of life to be poor 12 months after inpatient rehabilitation. There is an identified need for follow-up examinations of community dwelling stroke survivors to monitor changes in function and it has been suggested that maintenance therapy could curtail declines in function. The purpose of this trial is to determine whether brief periods of intense client-centered rehabilitation therapy (tune-ups) provided at 6 month intervals can alter the natural progression of impairment (physical capacity), function and community reintegration following stroke.


Options:
A: Arm Label: STARFISH intervention; Type: EXPERIMENTAL; Interventions: Behavioral: STARFISH intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: STARFISH intervention; Assigned to Arm(s): STARFISH intervention
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: STARFISH | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STARFISH; Assigned to Arm(s): Intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: physical rehabilitation | Intervention Type: BEHAVIORAL; Name: physical rehabilitation; Assigned to Arm(s): Intervention
D: Arm Label: ICoreDIST; Type: EXPERIMENTAL; Interventions: Procedure: ICoreDIST | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Intervention Type: PROCEDURE; Name: ICoreDIST; Assigned to Arm(s): ICoreDIST | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intracoronary Injection of CD133+ Autologous Hematopoietic Cells After Myocardial Infarction
Brief Summary: TITLE Intracoronary injection of CD133+ autologous hematopoietic cells after myocardial infarction.

TRIAL DESIGN Pilot phase I/II parallel group study, with an untreated control group.

SPONSOR IRCCS Ospedale Maggiore Policlinico Milano INDICATION Acute myocardial infarction (AMI). TARGET POPULATION Patients (pts) with AMI treated with Primary Coronary Angioplasty (PTCA) with successful recanalization but unsuccessful reperfusion (myocardial blush (MB) grade 0 or 1 and less than 70% ST segment elevation resolution (STeR) (see Poli et al., Circulation, 2002).

OBJECTIVES Primary:

1. To evaluate the safety of intracoronary injection of CD133+ cells from autologous bone marrow (ABM) and mobilized peripheral blood (MPB) in the target population.
2. To evaluate the efficacy, of the selective injection of CD133+ cells from ABM and MPB in the culprit vessel of the target population, on regional and global contractile function and on perfusion and metabolism of the infarcted area, depending on cell dose and comparing to controls.

   Secondary:
3. To evaluate the disease-related morbility of the target population.


Options:
A: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
B: Intervention Type: PROCEDURE; Name: cd133+cell intracoronary administration; Assigned to Arm(s): N/A
C: Arm Label: Provacel: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Provacel: Cohort 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Provacel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Provacel; Assigned to Arm(s): Provacel: Cohort 1, Provacel: Cohort 2, Provacel: Cohort 3, Provacel: Cohort 4 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BMSCs transplantation; Type: EXPERIMENTAL; Interventions: Procedure: Hypoxia-stressed BMSCs transplantation to cure MI | Arm Label: No BMSCs transplantation; Type: SHAM_COMPARATOR; Interventions: Procedure: Hypoxia-stressed BMSCs transplantation to cure MI | Intervention Type: PROCEDURE; Name: Hypoxia-stressed BMSCs transplantation to cure MI; Assigned to Arm(s): BMSCs transplantation, No BMSCs transplantation

Answer: B